Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $34.00 at JPMorgan Chase & Co.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) had its target price dropped by investment analysts at JPMorgan Chase & Co. from $39.00 to $34.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 292.16% from the stock's previous close.

Other research analysts have also recently issued research reports about the stock. Wedbush reissued an "outperform" rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Bank of America dropped their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. The Goldman Sachs Group dropped their price objective on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating for the company in a report on Monday, February 10th. HC Wainwright dropped their price objective on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Day One Biopharmaceuticals has an average rating of "Buy" and an average price target of $34.57.

Remove Ads

Day One Biopharmaceuticals Price Performance

DAWN traded down $0.43 on Wednesday, hitting $8.67. 1,337,084 shares of the stock were exchanged, compared to its average volume of 1,209,766. The firm has a market capitalization of $878.75 million, a price-to-earnings ratio of -8.42 and a beta of -1.38. Day One Biopharmaceuticals has a 12 month low of $8.02 and a 12 month high of $18.07. The business has a 50-day moving average of $11.77 and a two-hundred day moving average of $13.20.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analysts' expectations of $27.11 million. Equities research analysts expect that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares of the company's stock, valued at approximately $1,531,059.40. This represents a 8.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the sale, the insider now directly owns 1,034,015 shares of the company's stock, valued at $13,762,739.65. This represents a 2.82 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,064 shares of company stock valued at $651,225. 8.40% of the stock is currently owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

Several large investors have recently modified their holdings of DAWN. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after buying an additional 1,002 shares during the period. TimesSquare Capital Management LLC grew its position in shares of Day One Biopharmaceuticals by 8.2% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company's stock worth $25,460,000 after buying an additional 139,160 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth approximately $825,000. Quest Partners LLC grew its position in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after buying an additional 7,668 shares during the period. Finally, First Turn Management LLC acquired a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth approximately $13,204,000. Institutional investors and hedge funds own 87.95% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.